Medical Cannabis in Canada and Neurological Conditions

In Canada, medical cannabis starts with a health care provider’s authorization, and Health Canada has not authorized cannabis products to treat any specific disease or symptom. The regulator describes the research on medical uses as limited. This page explains the access rules and the official evidence statements as of 27 October 2026. It makes no treatment claims. Anyone considering cannabis for a health condition, including a neurological one, should talk to a health care provider.

How does a patient get access?

Health Canada’s page on medical use says patients authorized by their health care provider can still access cannabis for medical purposes. There are three routes:

1. Buy directly from a federally licensed seller, using a medical document signed by the health care provider.
2. Register with Health Canada to produce a limited amount for personal medical use.
3. Designate someone to produce it for them.

Subject to provincial or territorial age limits, authorized patients may also buy from authorized retail outlets or online platforms. A medical document can be returned to a seller or transferred to a different licensed seller.

How much can a patient possess?

The public possession limit for an authorized patient is the lesser of 150 grams or a 30-day supply of dried cannabis, on top of the 30 grams anyone may carry. A patient must be able to show a seller-issued registration document or a Health Canada certificate if law enforcement asks. Health Canada says personal storage limits at home were removed.

What does Health Canada say about the evidence?

Three statements matter most.

• Health Canada states it has not authorized cannabis products to treat any specific diseases or symptoms, and that legal products have not been reviewed to confirm they are safe or effective for specific conditions.
• Its consumer information says the evidence for the safety and efficacy of cannabis for medical purposes is “limited or unknown.”
• Its general information page says available research, although limited, suggests cannabis might relieve certain symptoms, including chronic non-cancer pain, multiple sclerosis-related pain and spasms, and chemotherapy-related nausea, and that “we don’t yet know or fully understand all of these risks.”

Where do neurological conditions fit?

The only neurological condition Health Canada names on the pages we reviewed is multiple sclerosis: it appears among the symptoms (pain and spasms, spasticity) where limited research suggests possible relief and among reasons Canadians report using cannabis. Health Canada says whether cannabis is appropriate for an individual should be decided with a health care practitioner. Its travel guidance also names two market-approved prescription drugs containing cannabis, Epidiolex and Sativex, as able to travel under the Cannabis Regulations subject to requirements; those are approved drugs, which is different from the cannabis sold in stores. We did not find a current official page that evaluates cannabis for other neurological conditions, so none are discussed.

Can medical cannabis cross a border?

No, not on a prescription alone. The Government of Canada says medical cannabis cannot cross a border unless authorized by Health Canada and the relevant authorities in every country involved, and that individual exemptions are issued only in rare and exceptional circumstances, such as palliative care. Details are on the travel, driving and growing page.

For the history of how access changed after court cases from 2000 to 2016, see the history page. The myths and facts page covers a few common claims about medical benefits.